Study of DS-5141b in Patients With Duchenne Muscular Dystrophy
Status:
Completed
Trial end date:
2020-10-20
Target enrollment:
Participant gender:
Summary
This is a phase I/II study to evaluate the safety, tolerability, efficacy, and
pharmacokinetic (PK) profile of DS-5141b in patients with Duchenne muscular dystrophy (DMD)
amenable to exon 45 skipping and to determine the dosage for subsequent studies.